TipRanks
Argent Biopharma (DE:H5O0)
FRANKFURT:H5O0
Germany Market
H5O0
Argent Biopharma
RESEARCH TOOLSreports

Argent Biopharma (H5O0) Ratios

1 Followers

Argent Biopharma Ratios

DE:H5O0's free cash flow for Q3 2025 was AU$0.40. For the 2025 fiscal year, DE:H5O0's free cash flow was decreased by AU$ and operating cash flow was AU$431.34. See a summary of the company’s cash flow.
Ratios
TTM
Jun 25Jun 24Jun 23Jun 22
Liquidity Ratios
Current Ratio
 ― 0.05 0.19 0.23 0.18
Quick Ratio
 ― 0.05 0.18 0.15 0.09
Cash Ratio
 ― 0.02 0.09 0.06 0.02
Solvency Ratio
 ― -0.70 -1.54 -0.98 -1.11
Operating Cash Flow Ratio
 ― -0.47 -0.86 0.00 0.00
Short-Term Operating Cash Flow Coverage
 ― -0.54 -1.17 0.00 0.00
Net Current Asset Value
AU$ ―AU$ -10.28MAU$ -9.07MAU$ -13.87MAU$ -15.59M
Leverage Ratios
Debt-to-Assets Ratio
 ― 7.40 3.36 0.10 0.06
Debt-to-Equity Ratio
 ― -1.02 -0.96 -0.20 -0.08
Debt-to-Capital Ratio
 ― 67.01 -24.18 -0.25 -0.08
Long-Term Debt-to-Capital Ratio
 ― -0.29 0.00 0.00 0.00
Financial Leverage Ratio
 ― -0.14 -0.29 -2.09 -1.32
Debt Service Coverage Ratio
 ― -0.97 -2.13 -32.69 -59.48
Interest Coverage Ratio
 ― -219.33 -301.01 -37.85 -46.28
Debt to Market Cap
 ― 3.05 1.71 0.00 0.00
Interest Debt Per Share
 ― 0.11 0.15 0.04 0.31
Net Debt to EBITDA
 ― -1.31 -0.43 -0.02 -0.02
Profitability Margins
Gross Profit Margin
―-126.69%76.50%22.86%42.82%
EBIT Margin
―-4586.90%-3049.63%-1915.19%-613.85%
EBITDA Margin
―-4484.80%-2914.38%-1770.00%-591.65%
Operating Profit Margin
―-4586.90%-2646.84%-2049.40%-460.46%
Pretax Profit Margin
―-4783.36%-3058.43%-1969.34%-623.80%
Net Profit Margin
―-4783.36%-3058.43%-1967.34%-614.71%
Continuous Operations Profit Margin
―-4783.36%-3058.43%-1969.34%-623.86%
Net Income Per EBT
―100.00%100.00%99.90%98.54%
EBT Per EBIT
―104.28%115.55%96.09%135.47%
Return on Assets (ROA)
―-595.44%-723.12%-162.51%-210.75%
Return on Equity (ROE)
―81.63%206.77%340.24%277.42%
Return on Capital Employed (ROCE)
―102.03%184.66%1315.01%461.79%
Return on Invested Capital (ROIC)
―-5166.99%4766.67%1567.67%489.40%
Return on Tangible Assets
―-595.44%-723.12%-162.51%-210.75%
Earnings Yield
―-246.96%-385.33%-139.31%-1726.83%
Efficiency Ratios
Receivables Turnover
 ― 0.67 1.55 1.87 6.38
Payables Turnover
 ― 0.48 0.08 0.72 0.89
Inventory Turnover
 ― 0.00 1.03 0.79 1.54
Fixed Asset Turnover
 ― 1.59 1.33 0.13 0.45
Asset Turnover
 ― 0.12 0.24 0.08 0.34
Working Capital Turnover Ratio
 ― -0.02 -0.06 -0.09 -0.57
Cash Conversion Cycle
 ― -219.90 -4.24K 151.82 -117.28
Days of Sales Outstanding
 ― 540.90 235.00 195.19 57.25
Days of Inventory Outstanding
 ― 0.00 353.15 464.69 237.35
Days of Payables Outstanding
 ― 760.80 4.83K 508.06 411.88
Operating Cycle
 ― 540.90 588.15 659.88 294.60
Cash Flow Ratios
Operating Cash Flow Per Share
 ― -0.05 -0.16 0.00 0.00
Free Cash Flow Per Share
 ― -0.05 -0.16 -0.39 -3.83
CapEx Per Share
 ― <0.01 <0.01 <0.01 0.25
Free Cash Flow to Operating Cash Flow
 ― 1.00 1.00 0.00 0.00
Dividend Paid and CapEx Coverage Ratio
 ― -2.49K -4.16K 0.00 0.00
Capital Expenditure Coverage Ratio
 ― -2.49K -4.16K 0.00 0.00
Operating Cash Flow Coverage Ratio
 ― -0.42 -1.12 0.00 0.00
Operating Cash Flow to Sales Ratio
 ― -24.97 -15.90 0.00 0.00
Free Cash Flow Yield
―-128.97%-200.43%-114.44%-933.72%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― -0.40 -0.26 -0.72 -0.06
Price-to-Sales (P/S) Ratio
 ― 19.37 7.94 14.12 0.36
Price-to-Book (P/B) Ratio
 ― -0.33 -0.54 -2.44 -0.16
Price-to-Free Cash Flow (P/FCF) Ratio
 ― -0.78 -0.50 -0.87 -0.11
Price-to-Operating Cash Flow Ratio
 ― -0.78 -0.50 0.00 0.00
Price-to-Earnings Growth (PEG) Ratio
 ― <0.01 <0.01 <0.01 >-0.01
Price-to-Fair Value
 ― -0.33 -0.54 -2.44 -0.16
Enterprise Value Multiple
 ― -1.74 -0.70 -0.82 -0.08
Enterprise Value
 ― 12.57M 11.89M 12.93M 1.54M
EV to EBITDA
 ― -1.74 -0.70 -0.82 -0.08
EV to Sales
 ― 77.98 20.39 14.51 0.45
EV to Free Cash Flow
 ― -3.12 -1.28 -0.90 -0.14
EV to Operating Cash Flow
 ― -3.12 -1.28 0.00 0.00
Tangible Book Value Per Share
 ― -0.11 -0.15 -0.16 -2.77
Shareholders’ Equity Per Share
 ― -0.11 -0.15 -0.14 -2.55
Tax and Other Ratios
Effective Tax Rate
 ― 0.00 0.00 0.00 >-0.01
Revenue Per Share
 ― <0.01 0.01 0.02 1.15
Net Income Per Share
 ― -0.09 -0.31 -0.47 -7.08
Tax Burden
 ― 1.00 1.00 1.00 0.99
Interest Burden
 ― 1.04 1.00 1.03 1.02
Research & Development to Revenue
 ― 3.04 6.16 2.61 0.59
SG&A to Revenue
 ― 41.56 13.81 9.73 3.58
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 0.52 2.50 0.00 0.00
Currency in AUD